References
- Swerdlow SH, Campo E, Harris NL, et al editors. WHO Classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon; 2008.
- Bari A, Marcheselli L, Sacchi S, et al Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010;21:1486–1491.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
- Sehn LH, Berry B, Chhanabhai M, et al The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
- Terasawa T, Lau J, Bardet S, et al Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–1914.
- Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
- Lenz G, Wright G, Dave SS, et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
- de Jong D, Rosenwald A, Chhanabhai M, et al Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
- Rydström K, Linderoth J, Nyman H, et al CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2010;51:1643–1648.
- Dupire S, Coiffier B. Targeted treatment and new agents in diffuse large B cell lymphoma. Int J Hematol. 2010 Jun 18. [Epub ahead of print].